Starpharma Deuda/Patrimonio neto
¿Qué es el Deuda/Patrimonio neto de Starpharma?
El Deuda/Patrimonio neto de Starpharma Holdings Limited es 0.31
¿Cuál es la definición de Deuda/Patrimonio neto?
La relación deuda / patrimonio neto es una relación financiera que indica la proporción relativa del capital contable y la deuda utilizada para financiar los activos de una empresa.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Deuda/Patrimonio neto de compañías en Sector Health Care en ASX en comparadas con Starpharma
¿Qué hace Starpharma?
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Empresas con deuda/patrimonio neto similar a Starpharma
- Blue Thunder Mining tiene Deuda/Patrimonio neto de 0.31
- Ironveld Plc tiene Deuda/Patrimonio neto de 0.31
- Nath Bio-Genes (India) tiene Deuda/Patrimonio neto de 0.31
- Greencoat UK Wind Plc tiene Deuda/Patrimonio neto de 0.31
- Ellex Medical Lasers tiene Deuda/Patrimonio neto de 0.31
- OssDsign AB (publ) tiene Deuda/Patrimonio neto de 0.31
- Starpharma tiene Deuda/Patrimonio neto de 0.31
- Anglesey Mining plc tiene Deuda/Patrimonio neto de 0.31
- Leyou Technologies tiene Deuda/Patrimonio neto de 0.31
- Orient Victory Travel tiene Deuda/Patrimonio neto de 0.31
- Eargo tiene Deuda/Patrimonio neto de 0.31
- Amuse tiene Deuda/Patrimonio neto de 0.31
- BeWhere tiene Deuda/Patrimonio neto de 0.31